Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Modern Radiotherapy Concepts for Hematological and Solid Malignancies
share announcement

Modern Radiotherapy Concepts for Hematological and Solid Malignancies

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Radiobiology and Nuclear Medicine".

Deadline for manuscript submissions: closed (18 February 2022) | Viewed by 3188

Special Issue Editors

Dr. Khaled Elsayad

E-Mail Website
Guest Editor
Radiation Oncology Department, University Hospital Munster, 48149 Münster, Germany
Interests: radiotherapy; sarcoma; lymphoma; cancer; imaging
Dr. Tamer Refaat

E-Mail Website
Guest Editor
Medical Director and MRI-guided Radiation Therapy Program Director, Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Stritch School of Medicine Loyola University Chicago, Maywood, IL 60153, USA
Interests: MRI-guided radiation therapy

Special Issue Information

Dear Colleagues,

In the modern era of radiation oncology, the main goal is to reduce treatment-related toxicities. This goal has led to the introduction of novel treatment approaches such as adaptive radiotherapy and de-escalation of radiation dose or volume. In this collection, we would like to provide Life readers with recent publications concerning radiotherapy advances and modern treatment concepts. Submissions discussing the role of modern radiotherapy in the treatment of solid or hematological neoplasms are strongly encouraged. The reviews and original studies are expected to enrich the literature and the scientific community.

Dr. Khaled Elsayad
Dr. Tamer Refaat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiotherapy
  • sarcoma
  • lymphoma
  • cancer
  • imaging
  • biomarkers
  • toxicity

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1552 KiB  
Article
Modified VMAT Plans for Locally Advanced Centrally Located Non-Small Cell Lung Cancer (NSCLC)
by Eva Y. W. Cheung, Virginia H. Y. Kwong, Fandy Y. C. Chan, Dominic Y. T. Cheng, Janice K. Y. Cheng, Sapphire H. Y. Yung, Kiris T. K. Chan, Kelly T. Y. Cheung, Tracy S. W. Cheung and Janna C. L. Yiu
Life 2021, 11(10), 1085; https://doi.org/10.3390/life11101085 - 14 Oct 2021
Cited by 2 | Viewed by 2198
Abstract
Objectives: This study aimed to find the optimal radiotherapy VMAT plans, that achieved high conformity and homogeneity to the planned target volume (PTV), and minimize the dose to nearby organs at risk including the non-PTV lung, heart and oesophagus for patients with centrally [...] Read more.
Objectives: This study aimed to find the optimal radiotherapy VMAT plans, that achieved high conformity and homogeneity to the planned target volume (PTV), and minimize the dose to nearby organs at risk including the non-PTV lung, heart and oesophagus for patients with centrally located non-small Cell Lung Cancer. Methods: A total of 18 patients who were treated for stage III centrally located non-small Cell Lung Cancer were selected retrospectively for this study. Identical CT datasets, 4D CT and structure dataset were used for radiotherapy planning based on single-planar VMAT (SP-VMAT), dual-planar VMAT (DP-VMAT) and Hybrid VMAT (H-VMAT). For SP-VMAT, one full arc and two half arcs were created on single-plane with couch at 0°. For DP-VMAT, one full arc was created with couch at 0°, and two half arcs with couch rotation of 330° or 30°. For H-VMAT, anterior-posterior opposing fixed beam and two half arcs were planned at couch at 0°. Dose constraints were adhered to the RTOG0617. Dose volumetric parameters were collected for statistical analysis. Results: There were no significant differences for the PTV, HI, CI between the SP-VMAT, DP-VMAT and H-VMAT. For the non-PTV lungs, Dmean, V20, V10, V5, D1500 and D1000 were significantly lower (2.05 Gy, 6.47%, 15.89%, 11.66% 4.17 Gy and 5.47 Gy respectively) in H-VMAT than that of SP-VMAT (all p < 0.001). For the oesophagus, Dmax, Dmean, V30 and V18.8 of H-VMAT were 0.08 Gy, 1.73 Gy, 5.54% and 7.17% lower than that of the SP-VMAT plan. For the heart, Dmean, V34, V28, V20 and V10 of DP-VMAT were lower than that of SP-VMAT by 1.45 Gy, 0.65%, 1.74%, 4.8% and 7.11% respectively. Conclusion: The proposed H-VMAT showed more favourable plan quality than the SP-VMAT for centrally located stage III NSCLC, in particular for non-PTV lungs and the oesophagus. It will benefit patients, especially those who planned for immunotherapy (Durvalumab) after standard chemo-irradiation. The proposed DP-VMAT plan showed significant dose reduction to the heart when compared to the H-VMAT plan. Full article
(This article belongs to the Special Issue Modern Radiotherapy Concepts for Hematological and Solid Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop